References
- MetzIRadueEWOterinoAPathology of immune reconstitution inflammatory syndrome in multifocal sclerosis with natalizumab-associated progressive leukencephalopathyActa Neuropathol201212323524522057786
- DownesSBlackGCHymanNSimmondsMMorrisJBartonCVisual loss due to progressive multifocal leukoencephalopathy in a congenital immunodeficiency disorderArch Opthalmol200111913761378
- CliffordDBDe LucaASimpsonDMArendtGGiovannoniGNathANatalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesLancet Neurol2010943844620298967
- HolmenCPiehlFHillertJA Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosisMult Scler20111770871921228027
- KapposLBatesDEdanGNatalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringLancet Neurol20111074575821777829
- SchröderALeeDHHellwigKLukasCLinkerRAGoldRSuccessful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosisArch Neurol2010671391139420625069
- VermerschPKapposLGoldRClinical outcomes of natalizumab- associated progressive multifocal leukoencephalopathyNeurology2011761697170421576685
- WarnkeCMengeTHartungHPNatalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and how can it be avoided?Arch Neurol20106792393020697042
- O’ConnorPWGoodmanAKapposLDisease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology2011761858186521543733
- SchaafSMPittDRackeMKWhat happens when natalizumab therapy is stopped?Expert Rev Neurother2011111247125021864070